MGA

Across TCGA pan-cancer cohorts, MGA Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated MGA data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher MGA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MGA expression acts as an unfavorable survival marker, although some lineages such as OV and BLCA show a favorable association.

MESO, KICH, and PRAD are the cancer types where MGA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
KICH	DFS	Median	All	0.043	0.971	<.001	21	view →
PRAD	DFS	Median	All	0.176	0.888	<.001	6	view →
COAD	DFS	Median	IV	0.035	0.501	<.001	6	view →
LGG	DFS	Median	All	0.118	0.826	<.001	3	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LIHC	OS	Median	II,III,IV	0.508	0.776	.022	3	view →
OV	OS	Median	IV	0.845	0.343	.031	2	view →
BLCA	OS	Median	III,IV	0.629	0.337	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

MGA–MESO (OS)

Open the MESO breakdown →